LeMaitre Vascular (LMAT)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$79.47-0.15%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Broken: Primary pillar broken — EPS reaches about $3.00 in FY26: FY26 EPS guidance mid $2.89 vs ~$3.00 target; Q2 GAAP EPS $0.74 vs $0.81 consensus.
LeMaitre Vascular grows revenue about 11% yearly, reaching $280M in 2026. Profit margins stay strong near 27%. The company raises dividends, showing steady shareholder returns. Operating income improved from $12.6M to $17.8M in one year.
Revenue growth could slow below 7%, hurting profits. Rising costs might reduce operating income and margins. Dividend increases may stall if cash flow weakens.
The stock price is about 43% above our valuation level, with analysts expecting 13% revenue growth. Our view sees growth and margins as solid but less likely to justify the current premium.
Breaks if: Dividend per share falls below $0.20
Breaks if: EPS falls below $2.48 in FY26
Breaks if: Operating margin falls below 24%
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity within the healthcare sector. The current thesis state reflects strong recent financial performance, but the company faces elevated risks that could impact its trajectory.
The market appears to have priced in a low level of fragility, indicating that expectations for LMAT are justified. The valuation is aligned with peers, suggesting that the current market sentiment is neutral.
Management has consistently delivered on its priorities, showing strong revenue and operating income growth. However, there is a low probability of missing earnings expectations, which is a risk to monitor given the company's recent history of earnings misses.
The future performance of LMAT hinges on guidance updates from management and the broader healthcare sector's performance. Key factors include whether sector leaders continue to beat earnings and how economic conditions affect cyclical names like LMAT.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Strong EPS growth supports revenue growth objectives. However, a guidance cut indicates potential revenue growth issues.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $247M in FY26
In the next 1 to 3 years, LMAT's performance will depend on its ability to maintain growth and navigate external risks. Not investment advice.